Markets:

Overview

News

Currencies

International

Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

11.64 +0.12 (+1.04%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >

Amneal (NASDAQ:AMRX) Misses Q1 Sales Targets, Stock Drops 11.3%

May 02, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 5.5% year on year to $695.4 million. On the other hand, the company’s...

Via StockStory

Amneal Reports First Quarter 2025 Financial Results

May 02, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Examining the Future: Amneal Pharmaceuticals's Earnings Outlook ↗

May 01, 2025

Via Benzinga

Amneal (AMRX) To Report Earnings Tomorrow: Here Is What To Expect

May 01, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings tomorrow before market hours. Here’s what investors should know.

Via StockStory

Earnings Scheduled For May 2, 2025 ↗

May 02, 2025

Via Benzinga

3 Profitable Stocks Skating on Thin Ice

April 29, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest

April 28, 2025

Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season.

Via StockStory

Topics Artificial Intelligence Intellectual Property

2 Reasons to Avoid AMRX and 1 Stock to Buy Instead

April 24, 2025

Over the past six months, Amneal’s shares (currently trading at $6.85) have posted a disappointing 17.6% loss while the S&P 500 was down 8.1%. This might have investors contemplating their next move.

Via StockStory

Topics Economy Government Stocks

3 of Wall Street’s Favorite Stocks That Concern Us

April 11, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month

April 11, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal to Report First Quarter 2025 Results on May 2, 2025

April 08, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal's Combination Drug Shows Improved Sleep Quality In Parkinson's Disease Patients ↗

April 07, 2025

Amneal shares data showing Crexont improves sleep and motor symptoms in Parkinson's patients, with Phase 4 trial underway for further evaluation.

Via Benzinga

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease

April 07, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

April 03, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

April 01, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks

March 13, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at generic pharmaceuticals stocks, starting...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Amneal to Participate at Upcoming Investor Conference

March 10, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers

March 05, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

March 03, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars ↗

February 28, 2025

Amneal Pharmaceuticals' Q4 sales rose 18% to $730.52M, surpassing estimates, while adjusted EPS missed. The company forecasts up to $3.1B in 2025 revenue.

Via Benzinga

Amneal’s (NASDAQ:AMRX) Q4 Sales Beat Estimates, Guides for Strong Full-Year Sales

February 28, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 18.4% year on year to $730.5 million. The company’s...

Via StockStory

Topics Artificial Intelligence Earnings Intellectual Property

Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

February 28, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Earnings Scheduled For February 28, 2025 ↗

February 28, 2025

Via Benzinga

Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow

February 27, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results tomorrow before market hours. Here’s what investors should know.

Via StockStory

Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock ↗

February 24, 2025

JP Morgan upgrades Amneal Pharmaceuticals, citing strong Crexont sales, robust generics growth, and a higher 2025 revenue forecast, with peak sales over $300 million.

Via Benzinga

Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks

February 21, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

February 19, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest

February 19, 2025

Via StockStory

Topics Artificial Intelligence Intellectual Property

Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks

February 14, 2025

Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season.

Via StockStory

Topics Artificial Intelligence Intellectual Property

ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group

February 13, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ:ANIP) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

Starting at $3.75/week.

Subscribe Today